New Lung Cancer Drug Improves Survival Rates

Friday, 21 Mar 2014 12:11 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink

Endocyte Inc said its experimental cancer drug, when used in combination with an approved treatment, improved survival rates without the disease worsening in a mid-stage study on patients with recurrent non-small cell lung cancer.
The company said the risk of the disease worsening or death was reduced by 25 percent for patients treated with the drug combination, compared with patients who only took the approved treatment.
 
ALERT: These 7 Things Activate Alzheimer’s In Your Brain

The trial tested the drug, vintafolide, in combination with a chemotherapy drug known as docetaxel in 199 patients who failed one prior treatment with chemotherapy.
The company's shares, which were halted prior to the news, closed at $14.64 on the Nasdaq on Thursday.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Comments
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved
> >